The Wall Street Journal
SCIENCE JOURNAL
By SHARON BEGLEY
A Smaller NIH Budget Means Fewer Scientists And 'Too-Safe' Studies
September 1, 2006; Page A11
(snip)
A few years ago Dr. Welch, a molecular oncologist at the University of Alabama, Birmingham, discovered a molecule that suppresses metastasis, the insidious process in which cancer cells break off from the primary tumor and seed distant sites in the body. He had planned to test whether the gene that makes this molecule, dubbed BRMS1, is turned off in women with metastatic breast cancer. If so, he hoped to design a treatment that would turn the gene back on, test it in mice and then, if all went well, in people.
But when he submitted the proposal to the National Institutes of Health, which funds most biomedical research in the U.S., he was turned down. He had gathered breast-cancer tissue samples and preliminary data from about 20 women showing that a turned-off BRMS1 gene is associated with metastatic breast cancer. A "study section" of scientists who evaluate proposals, however, said he needed data on hundreds of women (which he did not have the money to gather; Catch-22). Absent that, they gave his proposal too low a score to stay above the cutoff at which money ran out.
And so it has gone for an increasing number of biomedical researchers. Starting in 1995, the budget of the National Institutes of Health more than doubled, with support for scientist-initiated studies rising to $9.7 billion in fiscal 2003 from $4.3 billion in fiscal 1995. But in 2004, Congress and the White House, calling for reduced budgets in the wake of tax cuts and a growing deficit, slammed on the brakes. Ever since then, NIH's budget has been flat or, adjusting for inflation, down. The chance that a scientist's work will be funded fell to 22% last year from 27% in 1995, and to less than 10% in some fields. Now the warnings are coming true: The plug is being pulled on promising research by scientists with solid track records.
(snip)
NIH was never known for supporting risky ideas, but scientists say it has become even worse with the budget crunch. Grant reviewers are increasingly unwilling to gamble scarce money on speculative/bold (pick your adjective) approaches to understanding and treating disease... Dr. Schneyer estimates that some 5% of Massachusetts General Hospital scientists have only a few months left on existing grants and no new ones in sight. Although scientists may be "geneticists at MGH" or "neuroscientists at UCSF," unless they have tenure their salary comes out of a grant, not from the ostensible employer. As grants disappear, therefore, it isn't just that studies won't be done; researchers will have to look for another line of work, especially if they are Ph.D.s rather than M.D.s, who can at least see patients to bring in income.
(snip)
URL for this article:
http://online.wsj.com/article/SB115706406018051063.html (subscription)